Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

15.9%

772 terminated/withdrawn out of 4865 trials

Success Rate

81.8%

-4.7% vs industry average

Late-Stage Pipeline

26%

1243 trials in Phase 3/4

Results Transparency

63%

2171 of 3469 completed trials have results

Key Signals

231 recruiting2171 with results631 terminated141 withdrawn

Enrollment Performance

Analytics

Phase 1
1405(34.9%)
Phase 2
1090(27.0%)
Phase 3
795(19.7%)
Phase 4
448(11.1%)
N/A
273(6.8%)
Early Phase 1
20(0.5%)
4031Total
Phase 1(1405)
Phase 2(1090)
Phase 3(795)
Phase 4(448)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4865)

Showing 20 of 4865 trials
NCT05765500Phase 2Recruiting

RecoverPC: Relugolix vs GnRH Agonist in Quality of Life

Role: collaborator

NCT04996823Phase 2Active Not Recruiting

Axitinib + Ipilimumab in Advanced Melanoma

Role: collaborator

NCT07392892Phase 2Recruiting

Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

Role: lead

NCT06616194Phase 3Active Not Recruiting

A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

Role: lead

NCT05754658Completed

African Cancer Genome: GMD

Role: collaborator

NCT07489066Phase 2Recruiting

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

Role: lead

NCT06207799Phase 2Recruiting

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

Role: collaborator

NCT07174336Phase 3Recruiting

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Role: collaborator

NCT07028853Phase 3Recruiting

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

Role: lead

NCT04743141Phase 3Recruiting

Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

Role: lead

NCT07013474Phase 3Recruiting

A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

Role: lead

NCT05538130Phase 1Recruiting

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

Role: lead

NCT05357794Phase 2Recruiting

Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides

Role: collaborator

NCT07476287Phase 2Recruiting

Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

Role: lead

NCT04649242Phase 3Recruiting

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

Role: lead

NCT07733765Phase 3Not Yet Recruiting

A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata

Role: lead

NCT05327465Not ApplicableRecruiting

Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy

Role: collaborator

NCT03460977Phase 1Recruiting

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Role: lead

NCT07653100Phase 3Recruiting

A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF

Role: lead

NCT05156398Phase 3Recruiting

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

Role: lead